Schedule 13D ownership disclosure
Janux Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 47103J105
Event date: 2025-03-06
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 11,971,377.00 · Class: 19.9%
- Peter KolchinskyReported CIK 0001384859
Shares: 11,971,377.00 · Class: 19.9%
- Rajeev ShahReported CIK 0001619841
Shares: 11,971,377.00 · Class: 19.9%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 10,861,013.00 · Class: 18.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-007529
- Form type
- SCHEDULE 13D/A
- Filer
- Janux Therapeutics, Inc.
- CIK
- CIK 1817713
- Filed
- Mar 10, 2025
- Reporting period
- Mar 06, 2025
- Description
- Schedule 13D beneficial ownership